Publications - July 2022

Preprint and peer-reviewed publications from RECOVER’s studies

Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis

A recent prospective meta-analysis demonstrated that interleukin-6 antagonists are associated with lower all-cause mortality in hospitalised patients with COVID-19, compared with usual care or placebo. However, emerging evidence suggests that clinicians are favouring the use of tocilizumab over sarilumab. A new randomised comparison of these agents from the REMAP-CAP trial shows similar effects on in-hospital mortality. Therefore, we initiated a network meta-analysis, to estimate pairwise associations between tocilizumab, sarilumab and usual care or placebo with 28-day mortality, in COVID-19 patients receiving concomitant corticosteroids and ventilation, based on all available direct and indirect evidence.

Read more

ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), one of our partners within the RECOVER Consortium, has recently published a new paper on COVID-19 data. ISARIC is a global federation of clinical research networks that collaborates on the prevention of illness and death caused by infectious disease outbreaks through research response. The report focuses on a prospective, standardised, global dataset of patients that were hospitalised with COVID-19. 

Read more

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant (Huygens et al. 2022)

Viral evolution towards resistance against sotrovimab can explain treatment failure in most
immunocompromised patients and these patients can remain infectious after treatment. Therefore,
documenting viral clearance after treatment is recommended to avoid that these patients unintentionally become a source of new, sotrovimab resistant, variants. Research on direct acting antivirals and possibly combination therapy for the treatment of COVID-19 in immunocompromised
patients is needed.

Read article